Bottom line
XLV vs HRTS: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and HRTS (Tema Heart & Health ETF) share a meaningful slice of their top holdings — about 57% by weight.
XLV is cheaper at 0.08% vs 0.75% — a difference of $67 a year per $10,000 invested.
Over one year, HRTS returned +23.6% vs +14.5% for XLV.
Updated Nov 19, 2026
XLV vs HRTS side by side
| XLV | HRTS | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | Innovator |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.75% |
| Annual cost per $10k | $8 | $75 |
| 10-yr cost on $10k (prospectus) | $103 | $1,168 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +23.6% |
| 5-yr return (annualized) | +8.1% | — |
| 10-yr return (annualized) | +9.8% | — |
| Best quarter | +14.5% | +15.8% |
| Worst quarter | −12.7% | −12.4% |
| Net assets (fund) | $40.6B | $51.9M |
| Number of holdings | 65 | 45 |
| Portfolio turnover | 2% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | HRTS | Difference |
|---|---|---|---|
| 2025 | +14.5% | +23.6% | −9.1% |
| 2024 | +2.5% | +3.6% | −1.1% |
Source: Fund prospectus bar charts
Holdings overlap
15 of XLV's top 25 holdings also appear in HRTS's top 25.
| Holding | XLV | HRTS |
|---|---|---|
| Eli Lilly & Co | 16.51% | 11.52% |
| Johnson & Johnson | 10.64% | 3.59% |
| AbbVie Inc | 7.74% | 2.40% |
| UnitedHealth Group Inc | 6.57% | 5.24% |
| Merck & Co Inc | 5.52% | 4.27% |
| Amgen Inc | 3.40% | 1.91% |
| Thermo Fisher Scientific Inc | 3.24% | 3.97% |
| Abbott Laboratories | 2.75% | 2.61% |
| Gilead Sciences Inc | 2.73% | 3.43% |
| Vertex Pharmaceuticals Inc | 2.19% | 2.93% |
| Danaher Corp | 2.09% | 2.66% |
| Bristol-Myers Squibb Co | 2.05% | 2.09% |
| Medtronic PLC | 1.75% | 1.88% |
| McKesson Corp | 1.58% | 1.71% |
| Regeneron Pharmaceuticals Inc | 1.08% | 1.67% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
HRTS top 10
- Eli Lilly & Co — 11.52%
- UnitedHealth Group Inc — 5.24%
- Novo Nordisk A/S — 5.24%
- Roche Holding AG — 4.50%
- Merck & Co Inc — 4.27%
- AstraZeneca PLC — 4.00%
- Thermo Fisher Scientific Inc — 3.97%
- Johnson & Johnson — 3.59%
- Gilead Sciences Inc — 3.43%
- Novartis AG — 3.38%
FAQ
What is the difference between XLV and HRTS?
Which is cheaper, XLV or HRTS?
Should I own both XLV and HRTS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.